NEW YORK (GenomeWeb News) – Shimadzu and Indigo BioSystems announced that they have formed a partnership for the development of clinical mass spectrometry workflows.
Under the partnership, the two firms will combine Shimadzu's mass spec instruments with Indigo's Ascent clinical analysis software, a platform for interpreting mass spec data and automatically reviewing that data for problematic results.
The partnership will focus on developing mass spec solutions for applications in clinical research, forensic toxicology, and drug development, the companies said.
The Ascent software is aimed at streamlining mass spec data review, automatically scanning data for outliers, which can then be passed on for manual expert review. By passing on only potential outliers for expert review, the software can improve turnaround time and reduce costs per sample.
Financial and other terms of the agreement, which was announced at the American Society for Mass Spectrometry annual meeting being held in Baltimore this week, were not disclosed.